Minireview

DOI: 10.1159/000151436
Published online: August 18, 2008

Formula-Based Estimates of the GFR: Equations Variable and Uncertain

Pierre Delanaye\textsuperscript{a} Eric P. Cohen\textsuperscript{b}

\textsuperscript{a}Department of Nephrology-Dialysis, University of Liège, CHU Sart Tilman, Liège, Belgium; 
\textsuperscript{b}Department of Medicine, Medical College of Wisconsin, Froedtert Hospital, Milwaukee, Wisc., USA

Key Words
Glomerular filtration rate \cdot Creatinine \cdot MDRD

Abstract
Regarding the prevalence of chronic kidney disease in the population, estimation of glomerular filtration rate is of importance. Creatinine-based formulas are thus useful as the first step of a prevention strategy. Several creatinine-based formulas have been published. Among these, the Cockcroft-Gault formula and the Modification of Diet in Renal Disease (MDRD) study equation are the most used by physicians. The latter may be automatically reported by laboratories and has thus great success. However, these formulas have limitations. First, the MDRD formulas are not applicable to all populations, notably the healthy one and the patients with abnormal weight (anorectic or obese). Second, we evoke the limitations in the precision of the formulas linked to analytical aspects. Indeed, these analytical limitations remain significant even if they are improved by creatinine standardization. Lastly, we briefly mention the potential impact of these limitations on the epidemiology and the staging of chronic kidney disease.

Introduction
Identification and treatment of chronic kidney disease (CKD) is a major concern \cite{1,2}. Early diagnosis of progressive kidney disease is of the highest importance. Most doctors know the limitations of serum creatinine for the detection of early CKD \cite{3}. Serum creatinine concentration varies with the kidney function, and is also influenced by ‘non-nephrological’ factors such as sex, race, age and muscular mass. Due to these limitations, one can estimate glomerular filtration rate (GFR) with creatinine-based formulas that account for anthropometrical and biological variation \cite{1}. The two best known equations are the equation published in this journal by Cockcroft and Gault in 1976 \cite{4} and the most recent equation published by Levey et al. \cite{5} in 1999 using the data from the Modification of Diet in Renal Disease (MDRD) study (table 1). Table 2 compares the methodology and the population of both studies. The MDRD study estimates GFR in comparison to its measurement by the iothalamate method whereas the Cockcroft equation estimates creatinine clearance, which is not identical to the GFR, sensu stricto \cite{1}. The Cockcroft-Gault population was nearly all male. Another fundamental difference between these two formulas is the mean GFR of the population from which they have been built. These are, respectively, 39.8...
Limitations of the Creatinine-Based Equations

The Cockcroft-Gault equation uses the weight as a variable [4]. This is logical because the serum creatinine concentration varies with muscular mass. But weight is only an indirect estimation of the muscular mass. Inaccuracies in the equation thus occur when it is applied to obese or cachectic subjects. Several authors have shown the inaccuracy of the Cockcroft formula in these two populations [11, 12]. The Cockcroft formula could also be misleading when eGFR is longitudinally followed in an obese patient on a weight-loss diet. If the patient loses fat weight, the eGFR by Cockcroft will decrease, probably without a large decrease of true GFR. One may wonder why the weight variable does not appear in the MDRD study equation. This is explained by the fact that the MDRD equation indexes its GFR determination by the body surface area (BSA), and BSA takes into account the body height and weight. However, indexing GFR for BSA is questionable as we have already shown [13]. Indeed, indexing GFR for BSA implies that the relationship between GFR and BSA is linear and that this relationship disappears when indexed GFR is used. This is not true. Indexing GFR will have only minimal impact on the absolute results in the population with normal BMI. The impact of indexing will be high in obese patients [13]. The mean weight of the original MDRD population was 79.6 ± 16.8 kg. Most of the patients in the MDRD study were neither severely obese nor cachectic. Independently of the limitations linked to the BSA, Verhave et al. [12] have shown that the MDRD study equation underestimates

### Table 1. MDRD study equations and Cockcroft equation commonly used for GFR estimation

<table>
<thead>
<tr>
<th>Equation</th>
<th>Cockcroft and Gault</th>
<th>4-Variable MDRD study equation</th>
<th>4-Variable MDRD study equation (IDMS traceable)</th>
</tr>
</thead>
<tbody>
<tr>
<td>GFR (ml/min/1.73 m²) =</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SCr (mg/dl) – 1.154 × age – 0.203 × 0.742</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(if woman)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>× 1.21 for Black-American</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>× 0.763 for Japanese</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>× 1.233 for Chinese</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>186 × SCr (mg/dl) – 1.154 × age – 0.203 × 0.742</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(if woman)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>× 1.21 for Black-American</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>× 0.763 for Japanese</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>× 1.233 for Chinese</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Table 2. Comparison of methodology between the MDRD and the Cockcroft study

<table>
<thead>
<tr>
<th></th>
<th>Cockcroft</th>
<th>MDRD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sample</td>
<td>249</td>
<td>1,628</td>
</tr>
<tr>
<td>Mean GFR</td>
<td>73 ml/min</td>
<td>40 ml/min/1.73 m²</td>
</tr>
<tr>
<td>Reference method</td>
<td>Creatinine clearance</td>
<td>Iothalamate</td>
</tr>
<tr>
<td>% women</td>
<td>4</td>
<td>40</td>
</tr>
<tr>
<td>% black</td>
<td>unknown</td>
<td>12</td>
</tr>
<tr>
<td>Mean weight</td>
<td>72</td>
<td>79.6</td>
</tr>
<tr>
<td>BSA indexation</td>
<td>no</td>
<td>yes</td>
</tr>
</tbody>
</table>
measured GFR in obese patients by about 10 ml/min. The main limitation of this study is linked to the fact that most of the subjects had normal GFR and/or creatinine values [14]. We maintain that the use of formula-based estimates of the GFR is imprecise in obese and in underweight subjects, so that formulas are not suitable to search for CKD in these subjects, despite their possible predisposition to kidney disease.

**Analytical Limitation**

Due to the exponential relation of the serum creatinine to the GFR, a small change in low creatinine values will have great impact on the GFR. For example, if a patient’s creatinine increases from 0.6 to 1.2 mg/dl, this means that he has lost half of his initial GFR. However, if the creatinine rises from 3 to 3.6 mg/dl in a patient with the same anthropometrical data, the loss of GFR is considerably smaller. Thus, close-to-normal and normal serum creatinine values require attention.

**Calibration**

In 2002, Coresh et al. [15] illustrated the impact of differences in creatinine calibration on the GFR estimation. In the NHANES study, the serum creatinine was measured with the kinetic Jaffé method by the Roche assay on the Hitachi 737 machine, whereas in the MDRD study, the serum creatinine was measured with the Beckman method on the CX3 machine. Results of the serum creatinine measurement were systematically 0.23 mg/dl higher with the Hitachi method. For a 60-year-old white man with a Beckman serum creatinine of 1 mg/dl, the eGFR is 110 ml/min/1.73 m². The serum creatinine of the same patient will be 1.23 mg/dl on the Hitachi apparatus, which by the MDRD formula will give an eGFR of 81 ml/min/1.73 m². Further, and due to the exponential relation between GFR and creatinine, the impact of the differences of calibration will be greater for lower serum creatinine concentrations. The same difference in calibration will induce a difference of only 6 ml/min/1.73 m² in the eGFR for the same patient if his serum creatinine was 2 mg/dl. Others have confirmed the potential impact on the eGFR of the differences in creatinine calibration [16].

**IDMS-Traceable Creatinine**

The only way to overcome the potential bias linked to the calibration of creatinine is to calibrate the creatinine measurement against an absolute standard [17]. This standard does exist, and it is the measurement of creatinine by isotope dilution mass spectrometry (IDMS). Roche was the first to recalibrate the Jaffé and enzymatic methods to IDMS. Global calibration by other manufacturers is ongoing. Levey et al. [18, 19] have modified the MDRD formula based on these calibrations. In fact, for serum creatinine values traceable to the IDMS result, the factor 186 becomes 175. Nevertheless, the way this calibration has been obtained is not free from criticism. First, the authors have modified their equation after having recalibrated their Jaffé creatinine (Beckman CX3) to an enzymatic method (Roche Diagnostic) which has been calibrated with the IDMS reference method (fig. 1) [18]. Through their calibrations, the authors have deleted the different intercepts because they were not statistically significant. This is questionable. In fact, even if the intercept between Roche enzymatic and IDMS is not significant and even if the intercept between Roche enzymatic and Beckman CX3 is not significant, this does not necessarily imply that the intercept is not different for the regression of the IDMS versus the Beckman creatinine data! Indeed, Vickery et al. [20] have also measured the direct relation between creatinine measured by IDMS and Beckman CX3. These authors found a slope of 0.99 and an intercept of −0.18 mg/dl which is not negligible.

The second criticism regarding the IDMS calibration concerns the calibration curve between the Beckman CX3 creatinine and the Roche enzymatic creatinine (fig. 2). The calibration curve has been obtained on 40 reference sera with creatinine values between 0.5 and 5 mg/dl. From our point of view, the range of creatinine used for the calibration appears too large because, once again, calibration effect on the MDRD study results are only relevant in the lower values of creatinine (0.5–2 mg/dl). Within this specific range, the slope appears closer to 1, and not to 0.906 if higher values are included [21]. Accordingly, in a study concerning the creatinine calibration of the NHANES creatinine values, Selvin et al. [22] showed a slope of 1 between creatinine values measured with the Roche enzymatic method and the Beckman Jaffé...
fédé method used in NHANES 2001–2002 and 2003–2004 studies. In Selvin’s study, mean creatinine values used for calibration are in the important ‘low’ range (0.982 and 0.977 mg/dl). When one restricts the results of calibration between the Beckman Jaffé and Roche enzymatic creatinine determinations to the range of creatinine lower than 2 mg/dl, the regression coefficient between the two methods is close to 1. The factor 175 may be too low. The true factor should be closer than 186. The new choice of the factor 175 may contribute to the underestimation of eGFR by the thus modified MDRD study equation and to the overestimation of CKD [21, 23].

**Concepts of Critical Difference**

Even if we have criticized the way the new IDMS-traceable equation has been elaborated, we totally agree with the need for standardization of the methods of creatinine measurement. However, even when this harmonization will be obtained, all limitations of the creatinine-based equations will not disappear. One should know the concept of critical difference, which is fundamental for biological variables used for ongoing care of patients, as is the serum creatinine [24]. The critical difference can be defined as the smallest change in results which is not due to chance. It is dependent of the analytical coefficient of variation \( CV_a \) and the intra-individual (or biological CV) coefficient of variation \( CV_i \). In laboratories using Jaffé methods for creatinine measurement, \( CV_i \) for low creatinine values is 5.5%. The intra-individual coefficient of variation \( CV_i \) for creatinine is 4.3%. The critical difference for serum creatinine \( (= 1.414 \times 1.96 \times (CV_a^2 + CV_i^2)^{0.5}) \) is thus 19%. A creatinine value of 1 mg/dl is thus, from an analytical point of view, not different from 1.19 or 0.81 mg/dl. When the two latter values are used in the MDRD equation (for a white man of 60 years), the results are 66 and 103 ml/min/1.73 m\(^2\), respectively, while the eGFR for a serum creatinine of 1 mg/dl would be 81 ml/min/1.73 m\(^2\). The absolute differences between the lower and upper limit eGFRs and the eGFR value for a serum creatinine of 1 mg/dl are 15 and 22 ml/min/1.73 m\(^2\), respectively. Because the \( CV_a \) rises with decreasing creatinine values, the critical difference of creatinine is still higher for serum creatinine values below 1 mg/dl. Potential differences in creatinine-based formulae which are merely due to the analytical ‘error’ of measurement are thus not trivial.

The critical difference can be decreased with better \( CV_a \), but a lot of improvement seems difficult to obtain with the actual creatinine measurement. If a \( CV_a \) of 2% can be reached, notably with the enzymatic methods, the biological variation of creatinine is unchanged. With enzymatic methods, then, the critical difference could decrease to 13%, but variability of eGFR will remain. Using the numbers of the preceding example, these will be 14 and 11 ml/min/1.73 m\(^2\), respectively. To repeat, in normal creatinine ranges, small changes in creatinine concentrations have considerable consequences in GFR estimation and precision [25].

![Graph](image1.png)

**Fig. 2.** Roche enzymatic versus Beckman assays using calibration panel. **a** Intercept set to zero was not significant; slope 0.906, \( r^2 = 0.9994 \). **b** Bland-Altman plot [reproduced with permission from 18].
Other Limitations of the MDRD Study Equation

Impact on the CKD Classification

The classification of CKD was proposed in 2002 by the K/DOQI (Kidney Diseases Outcomes and Quality Initiative) and KDIGO (Kidney Disease Improving Global Outcomes) (table 3) [1]. The levels of GFR separating the different stages are much discussed [26]. That a subject with an eGFR >60 ml/min/1.73 m² always has true disease is questionable. This is especially true for older people because there is a natural decline in GFR with advancing age. The question of the ‘normal range’ of the GFR is still not fully resolved, as has been very elegantly shown by Glassock [26] in a recent editorial. We have illustrated the analytical limitations of creatinine that cause an imprecision of the MDRD study equation in the high values of GFR. These limitations are relevant to GFR estimation in the 60- to 90-ml/min range and all the more for higher ranges of eGFR. As we have shown, and even if traceability of creatinine and enzymatic methods are clear improvements, the precision in this range of GFR remains insufficient. This is acknowledged by Levey and colleagues [17] who recommend laboratories not to report the absolute values of the MDRD equation for results >60 ml/min/1.73 m², but simply to state that they are >60 ml/min/1.73 m². We extend this opinion to further state that to differentiate stage 1 CKD from stage 2 is unhelpful in clinical daily practice and should be abandoned. This has been also suggested by other authors [25, 27, 28] and is also stated in the Australian guidelines (CARI guidelines) [29].

Impact on the Epidemiology

Because the MDRD equation overestimates GFR, this equation will overestimate CKD prevalence in epidemiological studies [2]. For example, that 10% of the general population has true CKD is questionable [23, 26]. It remains possible that in the absence of progressive kidney disease, levels of GFR in the 60-90-ml/min range may carry cardiovascular risk, but this, too, is debatable, as is the entirely speculative effect of improving such levels of kidney function on that associated risk.

MDRD Study Equation in CKD Patients: An Estimate That Is Not Magic

In several studies, the MDRD study equation has been shown to be a good way to estimate the GFR in subjects with CKD [9]. However, in other subjects with kidney disease, the accuracy and the precision of the equation are less impressive. Thus, for hospitalized patients, especially those in intensive care and in transplantation, all formula-based estimates of eGFR are prone to substantial error [27, 30, 31]. This is not only because of reduced activity and muscle mass, but also because of day-to-day changes in kidney function. In all these patients, the MDRD study equation may be misleading.

MDRD Study Equation in Practice

In this review, we have underlined some limitations linked to formula-based estimates of the GFR. We agree that the MDRD study equation provides a good estimate of GFR, specifically in subjects with CKD who are in the steady state. We use and recommend that MDRD study equation results should be stated by clinical laboratories based on the serum creatinine, age, gender, and race, but without giving the absolute result when GFR is >60 ml/min/1.73 m². For particular populations, such as subjects on chronic dialysis and subjects with acutely changing kidney function, the formula-based estimates of GFR are false, and should be omitted or ignored. In any case, current formula-based estimates of the GFR remain estimations and we must keep this in mind when analyzing their results. The use of cystatin C as a new plasma marker of cystatin C and of cystatin C-based equations for better estimating GFR is increasing but it must be still validated before its implementation in daily clinical practice [32].
References


In this paper, Delanaye and Cohen critically review the validity of formulae used to estimate GFR. Their emphasis is on the limitations of the most commonly used MDRD and Cockcroft-Gault formulae. Their criticism, severe at times, reiterates concerns expressed by many nephrologists on the accuracy of these formulae for screening and detection of CKD within the general population. Clearly, such formulae have serious limitations at both spectra of CKD; CKD-1 and -2 as well as CKD-5. The authors also review adaptations to the MDRD formula for various non-Caucasian populations. These may facilitate the applicability of this formula in a number of countries and ethnicities. Finally, it has to be acknowledged that in spite of their limitations, the wide use of these formulae, especially amongst non-nephrologists, has focused minds on the degree of severity of CKD in a number of patients where it may have been overlooked in the past. Also, these formulae may open up the way in the future for new calculations, some based on serum cystatin C levels and others on a combination of serum creatinine and cystatin C, that may prove more accurate and adaptable.